<DOC>
	<DOCNO>NCT01711034</DOCNO>
	<brief_summary>The primary objective study determine safe tolerable dose level OPB-111077 patient advanced cancer .</brief_summary>
	<brief_title>A Phase 1 , Open-label , Multiple Dose Escalation Trial Determine Safety Tolerability Once Daily OPB-111077 Subjects With Advanced Cancer</brief_title>
	<detailed_description>The secondary objective study investigate pharmacokinetic property OPB-111077 ; pharmacodynamic effect OPB-111077 ; antitumor activity OPB-111077 assess RECIST IMWG Uniform Response Criteria ; explore whether PET response correlate measure clinical response .</detailed_description>
	<criteria>Pathologically and/or cytologically confirm advanced malignancy refractory standard therapy standard treatment option available For oral intravenous anticancer therapy , least 4 week 5 halflives , whichever short , need elapse since last dose Recovery adverse effect prior therapy time enrollment ≤ Grade 1 ( exclude alopecia ) Agreement forego chemotherapy , immunotherapy , radiotherapy , investigational drug enrol trial except hormonal therapy prostate cancer radiotherapy symptomatic bone metastasis know present Screening Male female subject age ≥ 18 year ECOG performance status ≤ 2 Adequate organ function Life expectancy ≥ 3 month follow trial entry For woman childbearing potential , negative serum pregnancy test result Screening For woman childbearing potential men whose sexual partner woman childbearing potential , agreement use 2 method adequate contraception prior trial entry , duration trial , 90 day last dose trial medication Signed date IRBapproved informed consent prior performance protocolspecific screen procedure Uncontrolled concurrent illness , include limited : ongoing active infection ; uncontrolled heart , liver , kidney , endocrine disorder Altered mental status , psychiatric illness , social situation would limit compliance trial requirement and/or obscure trial result Immunocompromised state Known evidence chronic viral hepatitis ( hepatitis B C virus ) Untreated symptomatic brain metastasis , subject leptomeningeal disease Inability swallow oral med gastrointestinal disorder might interfere absorption oral drug Major surgery within 28 day first receipt trial drug Nursing pregnant woman ≥ Grade 1 neuropathy pain &gt; Grade 2 neuropathy without pain ( subject neuropathy cause previous regimen recover ≤ Grade 2 stable without pain may include ) Foodeffect substudy ( Part B ) : Pathologies medical history might impair absorption elimination . PET scan substudy ( Part C ) : Uncontrollable blood glucose intolerance PET scan procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Solid tumor</keyword>
</DOC>